Maetzold Derek J's Form 4 filing
Castle Biosciences Inc (CSTL) · filed Apr 5, 2023
- Accession no.
- 0001447362-23-000052
- Filed
- Apr 5, 2023
- Trade date
- Apr 3-4, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Checked
This filing lists 14 non-derivative transactions. Open-market sales total $185.4K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Maetzold Derek JCIK 0001239501 | Director, Officer (Pres. & Chief Exec. Officer) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Apr 3, 2023 | Common Stock | SSaleDisposed | −2,391 | $22.15F2 | −$52,960.65 | 157,966 | Direct | |
| Apr 3, 2023 | Common Stock | SSaleDisposed | −1,196 | $22.15F2 | −$26,491.4 | 116,546 | Indirect | |
| Apr 3, 2023 | Common Stock | SSaleDisposed | −1,196 | $22.15F2 | −$26,491.4 | 105,441 | Indirect | |
| Apr 3, 2023 | Common Stock | SSaleDisposed | −596 | $22.15F2 | −$13,201.4 | 21,713 | Indirect | |
| Apr 3, 2023 | Common Stock | SSaleDisposed | −597 | $22.15F2 | −$13,223.55 | 21,713 | Indirect | |
| Apr 3, 2023 | Common Stock | SSaleDisposed | −597 | $22.15F2 | −$13,223.55 | 21,712 | Indirect | |
| Apr 3, 2023 | Common Stock | SSaleDisposed | −597 | $22.15F2 | −$13,223.55 | 21,705 | Indirect | |
| Apr 4, 2023 | Common Stock | SSaleDisposed | −401 | $22.10F9 | −$8,862.1 | 157,565 | Direct | |
| Apr 4, 2023 | Common Stock | SSaleDisposed | −200 | $22.10F9 | −$4,420 | 116,346 | Indirect | |
| Apr 4, 2023 | Common Stock | SSaleDisposed | −200 | $22.10F9 | −$4,420 | 105,241 | Indirect | |
| Apr 4, 2023 | Common Stock | SSaleDisposed | −101 | $22.10F9 | −$2,232.1 | 21,612 | Indirect | |
| Apr 4, 2023 | Common Stock | SSaleDisposed | −100 | $22.10F9 | −$2,210 | 21,613 | Indirect | |
| Apr 4, 2023 | Common Stock | SSaleDisposed | −100 | $22.10F9 | −$2,210 | 21,612 | Indirect | |
| Apr 4, 2023 | Common Stock | SSaleDisposed | −100 | $22.10F9 | −$2,210 | 21,605 | Indirect |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F2
This transaction was executed in multiple trades at prices ranging from $21.975 to $22.450, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.
- F9
This transaction was executed in multiple trades at prices ranging from $21.930 to $22.260, inclusive. The price reported above reflects the weighted-average sale price. The Reporting Person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
Referenced by the price of 7 transactions in Table I.